Maintaining qualification for 340B.

Area of Science:

• Health policy
• Healthcare administration
• Pharmaceutical economics

Background:

• The 340B Drug Pricing Program provides significant financial benefits to eligible healthcare organizations.
• Maintaining eligibility requires ongoing monitoring of patient demographics and payer mix.
• Changes in healthcare policy and patient enrollment can impact disproportionate share hospital status.

Purpose of the Study:

• To outline strategies for hospitals and health systems to maintain eligibility for the 340B Drug Pricing Program.
• To emphasize the importance of proactively managing patient qualification criteria.
• To highlight the role of patient enrollment in Medicare and Supplemental Security Income (SSI) in sustaining 340B status.

Main Methods:

• Review of 340B Program requirements and eligibility criteria.
• Analysis of patient enrollment data, particularly for Medicare and SSI.
• Monitoring of disproportionate share hospital status and SSI Ratio.

Main Results:

• Proactive management of the SSI Ratio is crucial for preventing declines in the Medicare patient base within the 340B program.
• Continuous tracking of patient eligibility for Medicare and SSI is essential, even amidst Medicaid expansion.
• Failure to monitor and manage these factors can jeopardize 340B program participation.

Conclusions:

• Hospitals must implement robust processes for monitoring patient eligibility and payer status to maintain 340B Drug Pricing Program participation.
• Strategic management of patient enrollment, particularly for Medicare and SSI, is key to long-term program success.
• Sustained qualification requires a proactive approach to healthcare policy and patient demographic tracking.